Info

🌱 來自: Phase I drug-metabolizing enzymes

CYP2C19

Involved in activation of thalidomide through 5-hydroxylation CYP2C19*2 homozygotes have shown poor metabolizing phenotype, may respond poorly to thalidomide tx